{"filings":[{"id":1553318,"accession_number":"0001213900-26-076715","cik":1946563,"company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTP","form_type":"8-K","filed_at":"2026-07-09T20:05:54+00:00","items":["8.01"],"status":"ready","headline":"60 Degrees files SAP for tafenoquine babesiosis trial; interim analysis criteria set","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["23 of 33 planned patients enrolled in randomized, placebo-controlled trial of tafenoquine for severe babesiosis (NCT0627370).","Interim analysis at earlier of 10/30/26 or after 24 patients randomized and followed ≥50 days.","Conditional power ≥80% for TTSCR with p≤0.02137 triggers early reporting; 50-80% triggers sample size reassessment (capped at 66 total).","Company intends to apply for a National Priority Review Voucher if results support sNDA submission before Q1 2028.","Sponsor and investigators remain blinded to interim analysis results if study continues."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":3749596.0799999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":835637,"accession_number":"0001213900-26-064796","cik":1946563,"company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTP","form_type":"8-K","filed_at":"2026-06-03T20:57:09+00:00","items":["8.01"],"status":"ready","headline":"60 Degrees Pharmaceuticals Plans to Seek FDA Priority Review Voucher for Tafenoquine in Babesiosis","summary_kind":"llm","event_type":"regulatory","confidence":"medium","bullets":["Company intends to apply for a Commissioner's National Priority Review Voucher if trial results support NDA submission by Q1 2028.","Tafenoquine is being evaluated in a randomized, placebo-controlled trial for patients hospitalized with severe babesiosis.","Application depends on interim or final analysis of the severe babesiosis trial supporting a New Drug Application.","Disclosure is provided to inform investors of current development and regulatory plans, subject to forward-looking risks."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3749596.0799999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":500157,"accession_number":"0001213900-26-058495","cik":1946563,"company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTP","form_type":"8-K","filed_at":"2026-05-18T20:33:00+00:00","items":["5.02"],"status":"ready","headline":"60 Degrees Pharmaceuticals appoints Eric Francois to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Eric Francois appointed to board effective May 13, 2026; compensation consistent with standard non-employee director arrangements.","Francois brings over 20 years of healthcare and life sciences leadership; currently independent director at CERo Therapeutics (CERO).","Previously CFO of SCYNEXIS (SCYX), raised over $300M through FDA approval and launch; earlier MD in healthcare investment banking at Raymond James and Credit Suisse.","No family relationships or material transactions with company; appointment not pursuant to any arrangement with others."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3749596.0799999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111160,"accession_number":"0001213900-26-032352","cik":1946563,"company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTP","form_type":"8-K","filed_at":"2026-03-20T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"60 Degrees Pharmaceuticals corrects beneficial ownership disclosure in March 13 prospectus","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["March 13 prospectus supplement incorrectly reported affiliate's beneficial ownership as 21,490 shares; correct is 23,367.","Error originated from a September 2025 Form 4 and propagated through subsequent filings.","Post-1-for-4 reverse split, corrected affiliate ownership is 16,781 shares vs previously reported 15,905.","No other information in the March 13 prospectus supplement is affected by this correction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":3749596.0799999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111159,"accession_number":"0001213900-26-027756","cik":1946563,"company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTP","form_type":"8-K","filed_at":"2026-03-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"60 Degrees Pharmaceuticals files updated legal opinion for ATM program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed updated legal opinion of Sichenzia Ross Ference Carmel LLP regarding shares sold under ATM Program.","Opinion confirms validity of shares sold under Sales Agreement dated September 5, 2025 with HC Wainwright & Co.","No changes to the terms of the ATM Program; opinion is procedural for ongoing offerings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":3749596.0799999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111158,"accession_number":"0001213900-26-027008","cik":1946563,"company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTP","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"60 Degrees Pharmaceuticals files updated legal opinion for ATM program","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Filed updated legal opinion from Sichenzia Ross Ference Carmel LLP regarding shares sold under ATM Program.","Opinion confirms validity of shares sold under Sales Agreement with HC Wainwright & Co. dated Sept 5, 2025.","No changes to terms of ATM Program; filing is procedural legal update."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":3749596.0799999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111157,"accession_number":"0001213900-26-015239","cik":1946563,"company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTP","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"60 Degrees Pharmaceuticals regains Nasdaq compliance on minimum bid price; delisting hearing cancelled","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Feb 11 confirming compliance with minimum bid price rule 5550(a)(2).","Prior delisting notice from Jan 20, 2026 was appealed and stayed pending hearing.","Hearing scheduled for Feb 19, 2026 has been cancelled; matter closed.","Company's common stock and warrants continue trading on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3749596.0799999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111156,"accession_number":"0001213900-26-007330","cik":1946563,"company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTP","form_type":"8-K","filed_at":"2026-01-23T23:59:59+00:00","items":["3.01","7.01"],"status":"ready","headline":"Nasdaq notifies 60 Degrees Pharmaceuticals of delisting for bid price rule violation","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq determined common stock failed $1.00 minimum bid price for 30 consecutive business days.","Company ineligible for compliance period due to 1-for-5 reverse stock split on Feb 24, 2025.","Warrants also subject to delisting under Nasdaq Listing Rule 5560(a).","Company paid $20,000 hearing fee and appealed, staying suspension pending panel decision.","No assurance the Nasdaq Panel will grant continued listing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3749596.0799999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111155,"accession_number":"0001213900-26-006179","cik":1946563,"company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTP","form_type":"8-K","filed_at":"2026-01-21T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"60 Degrees Pharmaceuticals to effect 1:4 reverse stock split effective Jan 20, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split at 1:4 ratio effective Jan 20, 2026 at 12:01 AM ET before market open.","Intended to regain compliance with Nasdaq minimum bid price requirement; symbol remains SXTP.","Shares outstanding reduce from ~5.15M to ~1.29M; fractional shares rounded up to whole share.","Approved by stockholders on Oct 8, 2025 and board on Dec 17, 2025; Delaware certificate filed.","All outstanding options, warrants, and equity plans adjusted proportionally."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3749596.0799999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111154,"accession_number":"0001213900-26-002359","cik":1946563,"company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTP","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"60 Degrees Pharmaceuticals provides investor presentation via RedChip webinar; no specific details disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company made investor presentation available on January 8, 2026, in connection with RedChip webinar.","Presentation covers updated clinical development timelines and regulatory strategy (no details disclosed).","Filing includes standard forward-looking statement disclaimer; no financial guidance provided.","Presentation exhibit (Ex. 99.1) contains only cover page and disclaimer, not slide content."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":3749596.0799999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127790,"accession_number":"0001213900-25-098131","cik":1946563,"company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTP","form_type":"8-K","filed_at":"2025-10-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"60 Degrees Pharma shareholders approve reverse split, equity plan amendment at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Five directors elected: Geoffrey Dow, Charles Allen, Cheryl Xu, Stephen Toovey, Paul Field.","Amendment to 2022 Equity Incentive Plan approved, increasing available shares by 250,000.","Reverse stock split authorized at ratio ranging from 1:3 to 1:10, as determined by the Board.","Ratification of RBSM LLP as independent registered public accounting firm for FY2025.","Adjournment proposal approved; quorum of ~40% of outstanding shares was present."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":3749596.0799999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144552,"accession_number":"0001213900-25-085853","cik":1946563,"company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTP","form_type":"8-K","filed_at":"2025-09-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"60 Degrees Pharmaceuticals presents at H.C. Wainwright; no specific updates disclosed in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["CEO Geoff Dow scheduled to present to investors starting September 9, 2025.","Slide deck furnished to investors; filing text does not contain its substantive content.","No financial figures, guidance, or pipeline milestones provided in the 8-K.","Company is an emerging growth company listed on Nasdaq under SXTP and SXTPW."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":3749596.0799999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144551,"accession_number":"0001213900-25-085040","cik":1946563,"company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTP","form_type":"8-K","filed_at":"2025-09-05T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"60 Degrees Pharmaceuticals enters $1.4M ATM offering with H.C. Wainwright, terminates prior ATM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered ATM Sales Agreement with H.C. Wainwright to sell up to $1,397,533 of common stock.","Wainwright receives 3.0% commission on gross proceeds; sales method is 'at the market'.","Terminated prior ATM agreement with Wallachbeth Capital LLC effective September 3, 2025, via waiver of notice period.","Issuance will be under existing Form S-3 shelf (File No. 333-280796) with a prospectus supplement.","Company has no obligation to sell any shares and may suspend or terminate the agreement at any time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3749596.0799999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144550,"accession_number":"0001213900-25-065718","cik":1946563,"company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTP","form_type":"8-K","filed_at":"2025-07-18T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"60 Deg Pharma closes $5M public offering, up to $10M with warrant exercise","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds $5M from sale of 2,631,578 units (share/pre-funded warrant + warrants) at $1.90/unit.","Short-term Series A-2 warrants (18-mo term) could add $5M if fully cash-exercised; no guarantee.","Net proceeds earmarked for working capital and general corporate purposes.","H.C. Wainwright acted as exclusive placement agent; offering closed July 16, 2025.","Offering made under effective S-1 filed July 7, 2025 (SEC File No. 333-288550)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3749596.0799999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162937,"accession_number":"0001213900-25-030102","cik":1946563,"company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTP","form_type":"8-K","filed_at":"2025-04-09T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"60 Degrees Pharma enters 12-month option for castanospermine license with Florida State","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered exclusive 12-month option to negotiate a royalty-bearing license for castanospermine purification technology.","Company holds 8.8 kg of Australian Chestnut extract inventory for potential botanical product commercialization.","Castanospermine is a bioactive alkaloid; company already owns IP on synthetic derivative celgosivir for viral diseases.","Company states the option agreement is not material to its business or operations.","Intends to explore non-prescription botanical extracts under changing U.S. regulatory framework."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":3749596.0799999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180876,"accession_number":"0001213900-25-010962","cik":1946563,"company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTP","form_type":"8-K","filed_at":"2025-02-06T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"60 Degrees Pharma raises $1.075M in registered direct offering plus warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $1.075 million from registered direct offering of 1,503,500 shares at $0.715 per share.","Concurrent private placement of warrants to buy 1,503,500 shares at $0.59 per share, exercisable for 24 months.","Net proceeds of approximately $908,627 after fees; total ~$2.118M raised from offerings since start of 2025.","H.C. Wainwright acted as exclusive placement agent and received fees and warrants (112,763 warrants at $0.8938).","Proceeds to be used for working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3749596.0799999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180875,"accession_number":"0001213900-25-008463","cik":1946563,"company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTP","form_type":"8-K","filed_at":"2025-01-30T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"60 Degrees Pharmaceuticals closes $1.043M registered direct offering and warrant private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 1,021,549 shares at $1.021/share; gross proceeds ~$1.043M.","Private-placement warrants for up to 2,043,098 shares at $0.771, exercisable for 24 months.","Net proceeds ~$804k after placement agent fees; H.C. Wainwright acted as agent.","Proceeds to be used for working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3749596.0799999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180874,"accession_number":"0001213900-25-007529","cik":1946563,"company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTP","form_type":"8-K","filed_at":"2025-01-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"60 Degrees Pharma announces IRB approval for Phase II study of tafenoquine in chronic babesiosis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IRB-approved open-label Phase II study (NCT06656351) evaluating tafenoquine for chronic babesiosis.","Patient enrollment expected to begin in Q3 2025; participants must have >6 months functional impairment.","Company estimates cumulative addressable market of >400,000 patients through end of U.S. patent protection in 2035.","No approved treatment currently exists for chronic babesiosis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3749596.0799999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180873,"accession_number":"0001213900-25-002070","cik":1946563,"company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTP","form_type":"8-K","filed_at":"2025-01-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"60 Degrees Pharmaceuticals enrolls first patient in expanded access study of tafenoquine for persistent babesiosis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient enrolled in NCT06478641, an expanded access study of tafenoquine for persistent babesiosis after standard-of-care failure.","Prior case series in Clinical Infectious Diseases reported 80% cure rate with tafenoquine plus SOC in five high-risk patients.","Company estimates cumulative U.S. accessible market for ARAKODA (tafenoquine) in babesiosis may exceed 400,000 patients through Dec 2035.","Tafenoquine is FDA-approved for malaria prophylaxis (ARAKODA) but not proven effective or approved for babesiosis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3749596.0799999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197732,"accession_number":"0001213900-24-095068","cik":1946563,"company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTP","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Shareholders approve reverse stock split, warrant exercise, and equity plan increase at special meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proposal to approve exercise of warrants for up to 6,014,493 shares passed with 259,282 for, 14,312 against.","Amendment to 2022 Equity Incentive Plan to increase shares by 500,000 approved: 253,106 for, 21,172 against.","Reverse stock split authorization (ratio 1:3 to 1:5) approved: 675,553 for, 77,032 against.","Adjournment proposal also approved: 674,854 for, 77,335 against.","Meeting held Nov 6, 2024; quorum of ~40.7% voting shares represented."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":3749596.0799999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197731,"accession_number":"0001213900-24-086079","cik":1946563,"company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTP","form_type":"8-K","filed_at":"2024-10-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"60 Degrees Pharmaceuticals launches 9-month promotional pilot for ARAKODA malaria drug","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nine-month pilot includes virtual sales reps and co-pay program to boost ARAKODA awareness and sales.","ARAKODA is the only FDA-approved antimalarial covering all stages of malaria, with weekly dosing.","Company plans expanded U.S. sales effort in 2025 based on pilot data.","CEO Geoffrey Dow says pilot will inform how healthcare professionals view ARAKODA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":3749596.0799999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213949,"accession_number":"0001213900-24-076515","cik":1946563,"company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTP","form_type":"8-K","filed_at":"2024-09-06T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"60 Degrees Pharmaceuticals raises ~$4M in private placement of common stock equivalents and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 2,898,551 pre-funded warrants and series A/B warrants at $1.38/share for gross proceeds of ~$4M.","Placement closed Sept. 5, 2024; H.C. Wainwright acted as exclusive placement agent.","Net proceeds to fund working capital, Arakoda commercialization, and R&D programs.","Warrants exercisable upon stockholder approval; Series A expire 5 years, Series B expire 18 months thereafter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3749596.0799999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213948,"accession_number":"0001213900-24-073351","cik":1946563,"company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTP","form_type":"8-K","filed_at":"2024-08-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"60 Degrees Pharmaceuticals regains Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Aug 26, 2024 confirming compliance with Listing Rule 5550(a)(2).","Achieved closing bid price of $1.00+ for 10 consecutive trading days from Aug 12 to Aug 23, 2024.","Closing price on Aug 23, 2024 was $1.81 per share.","Company had been notified of non-compliance on Feb 27, 2024 for bid price below $1.00."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3749596.0799999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213947,"accession_number":"0001213900-24-068942","cik":1946563,"company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTP","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"60 Degrees Pharma grants UK right of reference to ARAKODA NDA for SJ733 Phase IIb trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Granted University of Kentucky right of reference to ARAKODA NDA for FDA review of data supporting SJ733 Phase IIb study.","Phase IIb will combine SJ733 (oral ATP4 inhibitor) with tafenoquine for radical cure of Plasmodium vivax malaria.","Study funded by Global Health Innovative Technology Fund; Eisai managing trial material manufacturing and non-clinical studies.","60 Degrees Pharma will supply tafenoquine and placebos as study drugs for the trial."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3749596.0799999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213946,"accession_number":"0001213900-24-067535","cik":1946563,"company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTP","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"60 Degrees Pharmaceuticals effects 1:12 reverse stock split to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1-for-12 ratio effective August 12, 2024; new CUSIP 83006G203.","Split aims to bring stock price above Nasdaq's $1.00 minimum bid requirement.","Stockholders approved reverse split range on July 16; Board set exact ratio on July 19.","No fractional shares issued; all fractional amounts rounded up to one whole share.","Common stock symbol SXTP unchanged; warrants symbol SXTPW unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3749596.0799999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213945,"accession_number":"0001013762-24-001604","cik":1946563,"company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTP","form_type":"8-K","filed_at":"2024-07-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"60 Degrees Pharma awarded $311,862 U.S. Army contract for ARAKODA packaging validation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Awarded a fixed-price contract valued at $311,862 with U.S. Army Medical Materiel Development Activity for new bottle and replacement blister packaging of ARAKODA.","Contract aims to facilitate commercial validation to ensure continued U.S. government procurement of malaria prevention drug ARAKODA.","Q1 2024 ARAKODA net sales revenue increased 515% YoY to $105.7 thousand; company increased commercial batch size in Q1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3749596.0799999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213944,"accession_number":"0001213900-24-061853","cik":1946563,"company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTP","form_type":"8-K","filed_at":"2024-07-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"60 Degrees Pharma shareholders approve 1:5-1:12 reverse split and 5M share increase","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All five director nominees elected; each received >3.6M votes for.","Amendment to 2022 Equity Plan approved: 5M new shares authorized for issuance.","Reverse stock split authorized at ratio between 1:5 to 1:12, effective date to be set by board.","Modification of CEO/CFO option strike price and consultant option issuance both approved to comply with Nasdaq listing rules.","Ratification of RBSM LLP as independent auditor for FY2024 approved with 6.2M votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3749596.0799999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213943,"accession_number":"0001213900-24-060093","cik":1946563,"company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTP","form_type":"8-K","filed_at":"2024-07-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"60 Degrees Pharma enrolls first patient in tafenoquine babesiosis study at Tufts Medical Center","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IRB approval received for open-label expanded access study of tafenoquine in immunocompromised patients with persistent babesiosis.","Goal is to confirm 80% cure rate (30-100% CI) from Yale April 2024 case series published in Clinical Infectious Diseases.","Three-part program: acute hospitalized (enrolling), expanded access (announced), and chronic babesiosis (planned, gated by NC State study).","Company plans to file NDA for supplemental babesiosis indication by Q2 2026.","U.S. accessible market estimate: 38,000 acute immunosuppressed patients and at least 375,000 chronic babesiosis patients through 2035."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3749596.0799999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233160,"accession_number":"0001213900-24-056728","cik":1946563,"company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTP","form_type":"8-K","filed_at":"2024-06-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"60 Degrees Pharmaceuticals enrolls first patient in tafenoquine babesiosis trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient enrolled in randomized, double-blind, placebo-controlled trial at Tufts Medical Center.","Study is first and only clinical trial evaluating tafenoquine in human babesiosis patients.","Endpoints: time to sustained clinical resolution and molecular cure via FDA-approved nucleic acid test.","Study targets at least 24 and up to 33 patients; interim analysis planned; recruitment during 2024 tick season.","Tafenoquine (ARAKODA) already FDA-approved for malaria prophylaxis; orphan drug designation for babesiosis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3749596.0799999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233159,"accession_number":"0001213900-24-052167","cik":1946563,"company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTP","form_type":"8-K","filed_at":"2024-06-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"60 Degrees Pharmaceuticals receives FDA orphan drug designation for tafenoquine to treat acute babesiosis","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted orphan drug designation for tafenoquine for acute babesiosis; company qualifies for market exclusivity, tax credits, and exemption from certain FDA filing fees.","Company entered agreement with Tufts Medical Center for first clinical trial in human babesiosis patients; recruitment starts June 13, 2024, with at least 24 hospitalized patients.","Babesiosis is transmitted by deer ticks; up to 47,600 of ~476,000 annual Lyme patients may be co-infected with Babesia."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3749596.0799999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233158,"accession_number":"0001213900-24-039151","cik":1946563,"company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTP","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"60 Degrees Pharma gets FDA comments on tafenoquine babesiosis trial; no material changes needed","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA provided comments on the clinical trial protocol for tafenoquine in treating babesiosis on April 26, 2024.","No material changes to trial design required; company will address FDA questions and recommendations.","Preparatory actions continue; patient enrollment expected to begin later in 2024.","Tafenoquine is FDA-approved for malaria prophylaxis as ARAKODA but not yet for babesiosis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3749596.0799999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251312,"accession_number":"0001213900-24-022736","cik":1946563,"company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTP","form_type":"8-K","filed_at":"2024-03-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA delays response to 60 Degrees Pharma's babesiosis trial protocol to April 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA communicated intention to respond to babesiosis trial protocol in April 2024, not March 2024 as anticipated.","Company maintains preparations for June 1, 2024 start date as previously communicated.","Protocol submission is under existing IND; FDA has no specified response timeframe.","Tafenoquine (ARAKODA) is FDA-approved for malaria prophylaxis since 2018."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":3749596.0799999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251311,"accession_number":"0001213900-24-017634","cik":1946563,"company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTP","form_type":"8-K","filed_at":"2024-02-28T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"60 Degrees Pharma receives Nasdaq bid price deficiency notice; 180-day cure period","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified SXTP that common stock failed to maintain $1.00 minimum bid price for 31 consecutive business days through Feb 27, 2024.","Company has 180 calendar days, until August 26, 2024, to regain compliance with the Bid Price Rule.","If non-compliant by Aug 26, Company may be eligible for additional 180-day period if it meets other listing standards.","Company is evaluating options; there is no immediate effect on listing of SXTP or SXTPW on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3749596.0799999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251310,"accession_number":"0001213900-24-015295","cik":1946563,"company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTP","form_type":"8-K","filed_at":"2024-02-20T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"60 Degrees Pharmaceuticals sponsors pre-clinical study of tafenoquine against Candida auris with Monash University","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Animal studies will test tafenoquine efficacy against Candida spp, including drug-resistant Candida auris.","Monash University conducts studies; experiments start May 2024, completion by Nov 30, 2024.","Company to pay Monash $90,167 AUD on April 1, 2024 and $90,167 AUD on service completion.","Tafenoquine is FDA-approved for malaria prophylaxis; its antifungal mode of action is differentiated from standard care.","Results expected by end of 2024; earlier in vitro data showed broad-spectrum antifungal activity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3749596.0799999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251309,"accession_number":"0001575872-24-000114","cik":1946563,"company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTP","form_type":"8-K","filed_at":"2024-02-02T23:59:59+00:00","items":["8.01","1.01","9.01"],"status":"ready","headline":"60 Degrees Pharmaceuticals closes $2.4M public offering of units and pre-funded units","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$2.4M; net proceeds ~$1.9M after underwriter discounts and expenses.","Offering included 5,260,901 units at $0.385/unit and 999,076 pre-funded units at $0.375/unit.","Each unit consists of one share of common stock and one warrant (exercise price $0.4235, 5-year term).","Underwriters partially exercised over-allotment for 818,177 warrants.","Net proceeds to fund working capital, relaunch of ARAKODA malaria prevention, and R&D."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3749596.0799999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251308,"accession_number":"0001213900-24-005352","cik":1946563,"company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTP","form_type":"8-K","filed_at":"2024-01-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Following Jan 17 FDA meeting, 60 Degrees Pharma plans pivotal babesiosis study for tafenoquine","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA Type C meeting on Jan 17, 2024 led to mutual alignment on design of pivotal study for tafenoquine in hospitalized babesiosis.","FDA indicated proposed study could support approval if clinical endpoint used; company revising protocol accordingly.","Patient enrollment targeted to begin in summer 2024 at three northeastern U.S. hospitals.","Tafenoquine (ARAKODA) is FDA-approved for malaria prophylaxis but not yet for babesiosis; estimated 47,000 patients/year in U.S."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3749596.0799999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251307,"accession_number":"0001213900-24-003691","cik":1946563,"company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTP","form_type":"8-K","filed_at":"2024-01-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"60 Degrees Pharmaceuticals regains Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on Jan 10, 2024 confirming compliance with Bid Price Rule 5550(a)(2).","Closing bid price averaged $1.00 or more for 10 consecutive business days through Jan 9, 2024.","Previously received deficiency notice on Nov 2, 2023; delisting risk now resolved.","Company's common stock (SXTP) and warrants (SXTPW) continue trading on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3749596.0799999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":268873,"accession_number":"0001213900-23-083513","cik":1946563,"company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTP","form_type":"8-K","filed_at":"2023-11-03T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"60 Degrees Pharmaceuticals receives Nasdaq deficiency notice for bid price non-compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["On Nov 2, 2023, Nasdaq notified SXTP that its common stock failed to maintain minimum $1.00 closing bid price for 30 consecutive business days through Nov 1, 2023.","The company has a 180-day compliance period until April 30, 2024 to regain compliance with the Bid Price Rule.","If not compliant by April 30, 2024, SXTP may be eligible for an additional 180-day period if it meets other listing standards.","Failure to regain compliance may result in delisting of common stock and warrants from Nasdaq Capital Market.","The company is evaluating options to regain compliance, including potential reverse stock split."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":3749596.0799999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":268872,"accession_number":"0001013762-23-003541","cik":1946563,"company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTP","form_type":"8-K","filed_at":"2023-10-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"60 Degrees suspends Phase IIB tafenoquine COVID-19 study; pivots to malaria and babesiosis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company will not re-submit IND for Phase IIB study (ACLR8-LR) of tafenoquine in mild-to-moderate COVID-19 after FDA feedback made U.S. enrollment unfeasible.","Shifts focus to ARAKODA (tafenoquine) commercialization for malaria prophylaxis and preparation for Phase IIA study in hospitalized babesiosis patients.","ARAKODA sales increased 150% in Q2 2023 vs Q2 2022; plans to appoint chief commercial officer and submit pre-IND meeting request for babesiosis in Q4 2023.","FDA advice indicated placebo-controlled study allowed only when nirmatrelvir/ritonavir is not clinically appropriate, making patient recruitment very challenging."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3749596.0799999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":285970,"accession_number":"0001213900-23-077357","cik":1946563,"company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTP","form_type":"8-K","filed_at":"2023-09-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"60 Degrees Pharma withdraws COVID Phase IIB IND after FDA comments; will resubmit pending feasibility","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Withdrew IND for ACLR8-LR Phase IIB study of tafenoquine for COVID-19 due to FDA comments on study design.","Plans to submit revised IND in Q4 2023 pending assessment of feasibility to meet FDA expectations.","Paused start-up activities for the trial, decreasing short-term burn rate and improving cash position.","Will continue commercialization of ARAKODA (tafenoquine) for malaria and prepare IND for babesiosis.","Q2 2023 ARAKODA sales increased 150% YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3749596.0799999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":285969,"accession_number":"0001575872-23-001173","cik":1946563,"company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTP","form_type":"8-K","filed_at":"2023-07-17T23:59:59+00:00","items":["8.01","1.01","9.01"],"status":"ready","headline":"60 Degrees Pharmaceuticals prices $7.5M IPO of 1.4M units at $5.30/unit; shares begin trading July 12","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IPO of 1,415,095 units priced at $5.30/unit; each unit = 1 share + 1 tradeable warrant ($6.095 exercise) + 1 non-tradeable warrant ($6.36 exercise).","Gross proceeds ~$7.5M; net proceeds ~$7.5M after underwriter discounts and expenses; net used for clinical studies and working capital.","Shares and tradeable warrants began trading on Nasdaq on July 12 under symbols SXTP and SXTPW; underwriter over-allotment partially exercised.","IPO closed on July 14, 2023; WallachBeth Capital acted as sole bookrunner; officers/directors subject to 180-day lock-up through Jan 11, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":3749596.0799999996,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}